BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Immunol. Nov 20, 2026; 16(3): 125225
Published online Nov 20, 2026. doi: 10.5411/wji.125225
Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease
Chun-Ye Zhang, Ming Yang
Chun-Ye Zhang, Bond Life Sciences Center, University of Missouri, Columbia, MO 65212, United States
Ming Yang, Department of Surgery, School of Medicine, University of Connecticut, Farmington, CT 06030, United States
Author contributions: Zhang CY and Yang M designed, wrote, revised, and finalized the manuscript.
AI contribution statement: Artificial intelligence (AI) tool ChatGPT was used for grammar checking of this manuscript. The authors take full responsibility and accountability for the integrity, accuracy, originality, and scientific validity of the manuscript and all submitted materials.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ming Yang, PhD, Assistant Professor, Department of Surgery, School of Medicine, University of Connecticut, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu
Received: July 2, 2026
Revised: August 2, 2026
Accepted: October 16, 2026
Published online: November 20, 2026
Processing time: 141 Days and 1.4 Hours
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 1.3 billion people worldwide and is frequently associated with cardiovascular disease, type 2 diabetes, chronic kidney disease, and other metabolic disorders. A key feature linking these conditions is metabolic inflammation, or metainflammation, a state of chronic, low-grade inflammation driven by excessive lipid accumulation and adipose tissue dysfunction. Metainflammation promotes hepatic steatosis, inflammation, hepatocyte injury and ballooning, and fibrosis, thereby contributing to the development and progression of MASLD, as well as metabolic dysfunction and alcohol-associated liver disease (MetALD), which can lead to liver cirrhosis and hepatocellular carcinoma. These pathological processes are mediated through multiple interconnected mechanisms, including insulin resistance, dysregulated lipid metabolism, oxidative stress, fibrogenesis, and alterations in the gut microbiota. This review discusses the mechanisms underlying metainflammation in MASLD and MetALD and summarizes current and emerging therapeutic strategies targeting these pathogenic factors in preclinical studies and clinical trials.

Keywords: Metainflammation; Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction and alcohol-associated liver disease; Lipid metabolism; Immunity; Liver fibrosis; Clinical trials

Core Tip: Metainflammation contributes to the pathogenesis of numerous metabolic disorders and chronic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-associated liver disease (MetALD). It promotes hepatic lipid accumulation, inflammation, fibrosis, and cell death, thereby accelerating the progression of MASLD or MetALD to cirrhosis and liver cancer. Therapeutic strategies targeting metainflammation, including gut microbiome-directed therapies, dietary modulation, antioxidant interventions, and modulation of lipid metabolism, represent promising therapies for metabolic liver diseases.

Write to the Help Desk